Podocan 抗体 (C-Term)
Quick Overview for Podocan 抗体 (C-Term) (ABIN1881665)
抗原
See all Podocan (PODN) 抗体适用
宿主
克隆类型
标记
应用范围
克隆位点
-
-
抗原表位
- AA 571-602, C-Term
-
纯化方法
- This antibody is purified through a protein A column, followed by peptide affinity purification.
-
免疫原
- This PODN antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 571-602 amino acids from the C-terminal region of human PODN.
-
亚型
- Ig Fraction
-
-
-
-
应用备注
- WB: 1:1000
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
缓冲液
- Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
-
储存液
- Sodium azide
-
注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
储存条件
- 4 °C,-20 °C
-
有效期
- 6 months
-
-
-
: "Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study." in: Diabetes Care, Vol. 33, Issue 10, pp. 2250-3, (2010) (PubMed).
: "Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip. ..." in: American journal of human genetics, Vol. 85, Issue 5, pp. 628-42, (2009) (PubMed).
: "Podocan, a novel small leucine-rich repeat protein expressed in the sclerotic glomerular lesion of experimental HIV-associated nephropathy." in: The Journal of biological chemistry, Vol. 278, Issue 35, pp. 33248-55, (2003) (PubMed).
-
: "Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study." in: Diabetes Care, Vol. 33, Issue 10, pp. 2250-3, (2010) (PubMed).
-
- Podocan (PODN)
-
别名
- PODN
-
背景
- Negatively regulates cell proliferation and cell migration.
-
分子量
- 68976
-
NCBI登录号
- NP_001186009, NP_001186010, NP_001186011, NP_714914
-
UniProt
- Q7Z5L7
抗原
-